DermTech, Inc. announced the appointment of Mark Aguillard as chief commercial officer effective September 19, 2023. Mr. Aguillard will lead DermTech?s overall commercial strategy and execution. Mr. Aguillard is a proven commercial leader with over 20 years of experience driving growth through the development and commercialization of multiple, novel molecular diagnostics.

Prior to joining the Company, he served as the chief commercial officer of Epic Sciences, where he led the development and launch of a novel liquid biopsy, DefineMBC, designed to personalize treatment for patients with metastatic breast cancer. Prior to joining Epic, Mr. Aguillard served in commercial leadership roles with Myriad Genetics, binx health, OmniSeq and Eli Lilly & Company directing sales, marketing, medical affairs, customer success and market access teams across oncology and women?s health. Mr. Aguillard received his Bachelor?s in Business Administration with a major in Finance from Texas Tech University.